Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Pablo G. Legorreta net worth and biography

Pablo Legorreta Biography and Net Worth

CEO of Royalty Pharma

Pablo Legorreta has been our Chief Executive Officer and chairman since inception. Previously, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York. Mr. Legorreta is also a co-founder of Pharmakon Advisors, a leading provider of debt capital to the biopharmaceutical industry. Mr. Legorreta serves on several boards including the New York Academy of Sciences, Rockefeller University, Brown University, the Hospital for Special Surgery, Pasteur Foundation (the U.S. affiliate of the French Institute Pasteur), Open Medical Institute, Park Avenue Armory, Epizyme, Inc., ITB-Med Pharmaceuticals, Nefro Health and ProKidney, LLC. Mr. Legorreta was the founder and is currently Honorary Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and Provided by Tagnifi.

What is Pablo G. Legorreta's net worth?: The estimated net worth of Pablo G. Legorreta is at least $16.69 million as of June 28th, 2023. Mr. Legorreta owns 600,000 shares of Royalty Pharma stock worth more than $16,692,000 as of April 23rd. This net worth evaluation does not reflect any other investments that Mr. Legorreta may own. Learn More about Pablo G. Legorreta's net worth.
How old is Pablo G. Legorreta?: Mr. Legorreta is currently 59 years old. There are 4 older executives and no younger executives at Royalty Pharma. The oldest executive at Royalty Pharma is Mr. George Wingate Lloyd, Executive VP of Investments & Chief Legal Officer, who is 64 years old. Learn More on Pablo G. Legorreta's age.
How do I contact Pablo G. Legorreta?: The corporate mailing address for Mr. Legorreta and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on Pablo G. Legorreta's contact information.
Has Pablo G. Legorreta been buying or selling shares of Royalty Pharma?: Pablo G. Legorreta has not been actively trading shares of Royalty Pharma during the last ninety days. Most recently, on Wednesday, June 28th, Pablo G. Legorreta bought 130,000 shares of Royalty Pharma stock. The stock was acquired at an average cost of $29.51 per share, with a total value of $3,836,300.00. Following the completion of the transaction, the chief executive officer now directly owns 600,000 shares of the company's stock, valued at $17,706,000. Learn More on Pablo G. Legorreta's trading history.
Who are Royalty Pharma's active insiders?: Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (CEO), George Lloyd (EVP), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.
Are insiders buying or selling shares of Royalty Pharma?: In the last twelve months, Royalty Pharma insiders bought shares 4 times. They purchased a total of 485,388 shares worth more than $15,543,025.16. In the last twelve months, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 2,250,753 shares worth more than $72,415,950.97. The most recent insider tranaction occured on January, 4th when Director Rory B Riggs sold 35,702 shares worth more than $983,590.10. Insiders at Royalty Pharma own 18.7% of the company. Learn More about insider trades at Royalty Pharma.
Information on this page was last updated on 1/4/2024.

Pablo G. Legorreta Insider Trading History at Royalty Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/28/2023	Buy	130,000	$29.51	$3,836,300.00	600,000
6/12/2023	Buy	45,000	$33.00	$1,485,000.00	425,000
5/24/2023	Buy	150,000	$32.25	$4,837,500.00	380,000
5/16/2023	Buy	160,388	$33.57	$5,384,225.16	160,388
6/18/2020	Buy	20,000	$28.00	$560,000.00

Pablo G. Legorreta Buying and Selling Activity at Royalty Pharma

Royalty Pharma Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Today's Range

Now: $27.82

$27.22

$27.97

50 Day Range

MA: $29.72

$27.46

$31.33

2 Week Range

Now: $27.82

$25.92

$36.19

Volume

4,682,023 shs

Average Volume

2,660,089 shs

Market Capitalization

$16.62 billion

P/E Ratio

14.72

Dividend Yield

2.98%

Beta

0.45

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

From Paradigm Press | Ad